Displaying drugs 151 - 175 of 7273 in total
Nilotinib
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Inducers …
Dihydro-alpha-ergocryptine
Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. Both compounds are hydrogenated ergot derivatives. Alpha-dihydroergocryptine approved drug product...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Troglitazone
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …
Sparsentan
Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP3A Inducers …
Nabilone
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Estradiol benzoate
Estradiol Benzoate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP1A2 Substrates …
Verapamil
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs...
Approved
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2B6 Substrates …
Curcumin
Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
Sotagliflozin
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A4 Inducers …
Nifedipine
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine.[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer...
Approved
Matched Categories: … P-glycoprotein inducers ... P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers …
Methimazole
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …
Cortisone acetate
Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203]
Cortisone acetate...
Approved
Investigational
Matched Categories: … P-glycoprotein inducers ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers …
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendons) are replaced...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A Substrates …
Lemborexant
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A Inhibitors …
Hydrocortisone acetate
Approved
Vet approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A Substrates …
Methadone
Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A Inducers …
Thalidomide
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha...
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP2B6 Substrates …
Crizotinib
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Estradiol valerate
Estradiol Valerate (also known as E2V) is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore...
Approved
Investigational
Vet approved
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP1A2 Substrates …
Ivosidenib
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP2C8 Inducers …
Fluvoxamine
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2B6 Inhibitors …
Lopinavir
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability...
Approved
Matched Categories: … P-glycoprotein inducers ... P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C9 Inducers …
Pitolisant
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2D6 Inhibitors …
Methoxyflurane
An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug...
Approved
Investigational
Vet approved
Withdrawn
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2A6 Substrates ... Cytochrome P-450 CYP2B6 Substrates ... Cytochrome P-450 CYP3A Substrates …
Erlotinib
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C8 Inhibitors …
Displaying drugs 151 - 175 of 7273 in total